Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
female patient last received 2 doses of GARDASIL-9 in 2021 but did not complete the series; No additional AE; This spontaneous report was received from a nurse referring to a 27-year-old female patient. No information regarding the patient's pertinent medical history, drug reactions or allergies, or concomitant therapies was provided. On an unknown date in 2021, she received the first and second dose of Human Papillomavirus 9-valent vaccine, recombinant suspension for injection for prophylaxis (dose, route of administration, vaccination scheme frequency, anatomical location, lot number, and expiration date were not reported), the reporter did not know why patient did not receive the 3rd dose (Inappropriate schedule of product administration). There was not adverse event reported (No adverse event).